Monte Rosa Therapeutics, Inc.
No SEC Form 4 filings for $GLUE in the last 30 days.
See all $GLUE insider activity →Monte Rosa Therapeutics (GLUE) will present Phase 1 study results for MRT-8102, a treatment for elevated cardiovascular disease risk, on October 1. The presentation will include safety and activity data from a 4-week trial. The webcast will be available on the company's website and archived for 30 days.
Monte Rosa Therapeutics (GLUE) received a $50M milestone payment from Novartis (NVS) for the first patient dosed in a Phase 2 trial of MRT-6160 for Sjögren’s disease. The deal could be worth up to $2.1B. Monte Rosa reported Q2 2026 revenue of $9M, up from $23.2M a year earlier, with a net loss of $43.4M. The company has multiple clinical trials ongoing and $626M in cash.
Monte Rosa Therapeutics (GLUE) announced that Novartis has initiated a Phase 2 study for MRT-6160 (DDY391) in Sjögren's disease patients. Monte Rosa will receive a $50 million milestone payment. The study is part of a global license agreement where Novartis has exclusive rights to develop and commercialize VAV1 MGDs, with Monte Rosa eligible for up to $2.1 billion in milestones.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning GLUE (Monte Rosa Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent GLUE coverage spans corporate actions, technology and financial news.
The market will price in the Phase 1 data, creating near‑term volatility.
The cash infusion improves Monte Rosa's runway and may lift the stock on the news.
Positive catalyst likely to boost GLUE share price on milestone receipt and trial commencement.
The cash infusion improves Monte Rosa's balance sheet and validates its platform, likely supporting a near‑term share price uplift.
Milestone payment boosts cash and validates partnership with Novartis.
AlphAI scores every news story that mentions GLUE with an AI model for sentiment and relevance, and aggregates insider trades from Monte Rosa Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Monte Rosa Therapeutics (GLUE) will present Phase 1 study results for MRT-8102, a treatment for elevated cardiovascular disease risk, on October 1. The presentation will include safety and activity data from a 4-week trial. The webcast will be available on the company's website and archived for 30 days.
2 min readMonte Rosa Therapeutics (GLUE) received a $50M milestone payment from Novartis (NVS) for the first patient dosed in a Phase 2 trial of MRT-6160 for Sjögren’s disease. The deal could be worth up to $2.1B. Monte Rosa reported Q2 2026 revenue of $9M, up from $23.2M a year earlier, with a net loss of $43.4M. The company has multiple clinical trials ongoing and $626M in cash.
3 min readMonte Rosa Therapeutics (GLUE) announced that Novartis has initiated a Phase 2 study for MRT-6160 (DDY391) in Sjögren's disease patients. Monte Rosa will receive a $50 million milestone payment. The study is part of a global license agreement where Novartis has exclusive rights to develop and commercialize VAV1 MGDs, with Monte Rosa eligible for up to $2.1 billion in milestones.
2 min readMonte Rosa Therapeutics (GLUE) received a $50 million milestone payment as Novartis initiated a Phase 2 trial for MRT-6160, a treatment for Sjögren’s disease. The trial will evaluate the drug's efficacy and safety over 52 weeks. Monte Rosa could earn up to $2.1 billion in future milestones and a 30% share of U.S. profits.
2 min readNovartis (NVS) has begun a Phase 2 study of MRT-6160 for Sjögren’s disease. Monte Rosa Therapeutics (GLUE) will receive a $50M milestone payment. The study aims to evaluate efficacy, safety, and tolerability of the treatment. MRT-6160 is a VAV1-directed molecular glue degrader. Novartis holds exclusive rights under a licensing agreement, with Monte Rosa eligible for up to $2.1B in milestones.
2 min readMonte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study und
2 min readMonte Rosa Therapeutics (GLUE) shares dropped 4.8% after initiating a phase 2 study for MRT-2359 in mCRPC patients with AR mutations. The study will enroll up to 25 patients, with endpoints including PSA response and safety. The company previously reported positive phase 1/2 data for MRT-2359 combined with enzalutamide.
1 min readMonte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.
1 min readMonte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to
6 min readBioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) fell after Novo Nordisk (NVO) reported its late-stage ZEUS trial for ziltivekimab failed to reduce heart attack, stroke, and related deaths despite lowering inflammation markers. BIOA dropped 64% and GLUE about 27%. Analysts cut BIOA and GLUE price targets while keeping Buy ratings.
4 min read
